Israeli biotech co Nectin Therapeutics raises $10m
#Investment
May 16, 2023
www.businesswire.com
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
undefined
Feb 7, 2023
www.biospace.com
Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace
#Partners
Dec 1, 2022
en.globes.co.il
Israeli co Nectin Therapeutics raises $25m
#Investment #Expand
Nov 30, 2022
www.prnewswire.com
Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
#Investment #Expand
Mar 7, 2022
www.prnewswire.com
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy
Israeli biotech co Nectin Therapeutics raises $10m
#Investment
May 16, 2023
www.businesswire.com
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
undefined
Feb 7, 2023
www.biospace.com
Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace
#Partners
Dec 1, 2022
en.globes.co.il
Israeli co Nectin Therapeutics raises $25m
#Investment #Expand
Nov 30, 2022
www.prnewswire.com
Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
#Investment #Expand
Mar 7, 2022
www.prnewswire.com
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy